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Aspergillus fumigatusA limited therapeutic arsenal against increasing clinical disease due to Aspergillus spp. necessitates
urgent characterisation of new antifungal targets. Here we describe the discovery of novel, low
micromolar chemical inhibitors of Aspergillus fumigatus family 18 plant-type chitinase A1 (AfChiA1)
by high-throughput screening (HTS). Analysis of the binding mode by X-ray crystallography
conﬁrmed competitive inhibition and kinetic studies revealed two compounds with selectivity
towards fungal plant-type chitinases. These inhibitors provide new chemical tools to probe the
effects of chitinase inhibition on A. fumigatus growth and virulence, presenting attractive starting
points for the development of further potent drug-like molecules.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical
Societies. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/3.0/).1. Introduction
Aspergillus fumigatus is a ﬁlamentous opportunistic fungus and
regarded as one of the most pernicious pathogens in immunosup-
pressed individuals. The spectrum and burden of clinical disease
due to A. fumigatus is becoming increasingly recognised [1,2].
Neutropenia in patients with haematological malignancies
remains an important risk factor for invasive pulmonary aspergil-
losis (IPA). Despite therapeutic management, overall mortality
remains around 50% for IPA [1], increasing up to 90% in dissemi-
nated disease [3]. Evidence is emerging that chronic pulmonary
aspergillosis, affecting approximately 3–5 million patients globally
[1,4], may be alleviated by adjunct long-term oral antifungal ther-
apy [5]. These contrasting infections rely on a limited repertoire of
antifungal classes (polyenes, azoles and echinocandins), none of
which are without signiﬁcant drawbacks in terms of toxicity,
drug–drug interactions and/or efﬁcacy [6–8]. Azole resistancethrough one of several lanosterol 14 a-demethylase (cyp51A)
mutations or environmental sources is an increasing concern [9].
With no new antifungal classes in the immediate pipeline, what
is urgently needed is the characterisation of targets possessing
novel modes of action [10].
The fungal cell wall is a complex polysaccharide composed
predominantly of chitin, b-(1,3) glucan and galactomannan that
provides structural stability and is essential for survival [11].
Chitin, a linear polymer of b-(1,4) linked N-acetylglucosamine (Glc-
NAc) forms the rigid inner layer of the cell wall and is also partially
hydrolysed during morphogenesis [11]. This is performed by
glycoside hydrolase family 18 (GH18) chitinases that catalyse the
cleavage of b-(1,4) glycosidic bonds between GlcNAc residues.
While GH18 chitinases are found in all kingdoms of life [12], chitin
is absent in mammalian cells and these enzymes have been consid-
ered potential drug targets [13].
In A. fumigatus there are 17 chitinase genes phylogenetically
divided into three subgroups forming two broad families [14–
16]: subgroup B ‘‘plant-type’’ (chiA1–5, class III) and subgroup A/
C ‘‘bacterial-type’’ (chiB1–12, class V). The latter, found most
frequently in bacteria and also humans, are almost exclusively sol-
uble secreted enzymes with exochitinase activity and unclear
physiological function [11]. In contrast, ‘‘plant-type’’ enzymes are
predominantly cell wall associated endochitinases. These endoch-
itinases are potentially attractive antifungal targets, as they
(i) provide selectivity since the distant human orthologues are
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pose a formidable challenge as a family containing presumably
redundant genes. Comprehensive genetic validation involving tar-
geted disruption of all 17 genes in a single strain is not feasible.
Neither a quintuple mutant deleting all ﬁve plant-type chitinase
genes [16] nor a single deletion of chiB1 in A. fumigatus yielded a
signiﬁcant phenotype under standard growth conditions [17].
Interestingly, recent work suggests chitinases may be involved in
bioﬁlm maturation [18]. A fungal bioﬁlm is deﬁned as a surface
associated, highly structured community of hyphae encased by a
polysaccharide extracellular matrix [19,20]. Most clinical infec-
tions are bioﬁlm related and, taken together, this ﬁnding sparked
further investigation into chitinases as potential antifungal targets.
A crucial ﬁrst step is the generation of potent chemical tools to
probe concurrent inhibition of all A. fumigatus chitinases, and thus
allow for investigation of chemical validation as an alternative to
genetic validation.
The natural product allosamidin was the ﬁrst chitinase inhibitor
reported [21]. This pseudotrisaccharide structurally mimics chitin
and competitively inhibits all characterised GH18 family chitinas-
es, albeit in the mid-micromolar range for the plant-type chitinase
class. Limited availability and unfavourable chemical characteris-
tics preclude use as a tool for chemical validation. Crucially, within
the separate two families, A. fumigatus chitinases possess highly
conserved active sites [22,23], suggesting that it may be possible
to generate separate pan-AfChiAx and pan-AfChiBx inhibitors that
could be combined to investigate the phenotype of inhibiting all
17 chitinases concurrently. While inhibitors originally designed
to inhibit AfChiB1 also potently inhibit other ‘‘bacterial-type’’
chitinases [22,24], a potent nanomolar AfChiAx inhibitor to allow
chemical validation of this attractive class of targets remains elu-
sive. Natural product derivatives based on fragments of the bacte-
rial-type chitinase inhibitor argiﬁn yielded micromolar inhibitors
of A. fumigatus chitinase A1 (AfChiA1) [23]. Another study screened
a model fungal plant-type chitinase, Saccharomyces cerevisiae CTS1
(ScCTS1) against a library containing 880 off-patent drugs [25].
Despite extensive optimisation through structure-based activity
relationships, derivatives failed to improve the potency of the par-
ent compound, acetazolamide (AfChiA1 IC50 164 lM) [26].
Having exhausted all previous tractable chemical starting
points we performed a high-throughput screen (HTS) of approxi-
mately 60,000 compounds against AfChiA1. Here we describe the
discovery of the most potent, novel, low micromolar scaffolds
reported to date together with the crystal structures of the enzyme
in complex with hits selective for plant-type chitinases.
2. Materials and methods
2.1. AfChiA1 cloning, expression and puriﬁcation
AfChiA1 (Arg28-His337) was expressed and puriﬁed as
described previously [23]. In brief, the enzyme was expressed in
Pichia pastoris as a secreted protein, the culture supernatant was
dialysed, concentrated and AfChiA1 puriﬁed using anion exchange
followed by size exclusion chromatography. This protein sample
was then used for the HTS, kinetics and structural biology
described below.
2.2. AfChiA1 enzyme assay and high-throughput screen
Information according to published guidelines on the standard-
ised reporting of HTS [27] is provided in Table S1. The Dundee Drug
Discovery Unit (DDU) diversity set of 59,904 compounds was sol-
ubilised in DMSO (ﬁnal maximum assay concentration of 1% (v/v)
in all samples including controls) and a HTS performed in singlet at
a concentration of 30 lM. Library compounds and DMSO controlswere transferred to 384-well black polystyrene plates (Matrix)
using a Hummingbird (Genomic Solutions). Columns 1–22
received library compounds, columns 23 and 24 were reserved
for high/low controls (DMSO) and an 8-point standard inhibitory
curve with acetazolamide (Sigma), a micromolar AfChiA1 inhibitor
[26]. Quality control (QC) plates, two per six assay plates, consisted
of low control (columns 1–10), high control (columns 11–20) and a
standard curve (columns 21–24). AfChiA1 catalyses the hydrolysis
of chitin and an existing assay liberating 4-methylumbelliferyl
(4-MU) from the ﬂuorogenic substrate 4-methylumbelliferyl b-D-
N,N0,N00-triacetylchitotrioside (4-MU-GlcNAc3, Sigma) was opti-
mised for microtitre plate format compatible with HTS [26].
AfChiA1 activity was assayed in McIlvaine’s buffer (100 mM citric
acid, 200 mM sodium phosphate [pH 5.5]) and 0.05 mg/ml BSA
(Pierce) in a ﬁnal reaction volume of 42 ll. Each reaction contained
10 nM AfChiA1 except eight wells in column 24 (screening plates)
and columns 1–10 (QC plates), to which only buffer was added to
determine background signal. The reaction was initiated by
100 lM 4MU-GlcNAc3 and both additions were executed using a
FlexDrop reagent dispenser (PerkinElmer). Assay plates were incu-
bated on a microtitre plate shaker (Heidolph) at room temperature
for 70 min. Fluorescence generated from the release of 4-MU was
quantiﬁed using an EnVision 2102 multilabel reader (Perkin
Elmer).
2.3. Data analysis
The Activity Base Suite (Abase) version 5.4 from IDBS was used
for all data processing and analyses. For all compounds, the raw
relative ﬂuorescent units (RFUs) were corrected and normalised
to percentage inhibition (PI) according to the equations in
Table S1. Calculation of the Z-factor to determine the quality of
the screening assay was as follows [28]:
Z-factor ¼ 1 ð3 SDhigh control þ 3 SDlow controlÞ=

Meanhigh control Meanlow controlÞ
 
for which SDhigh control and SDlow control represent the standard
deviations of the response from 8 to 12 control wells (uninhibited
signal) and 8 to 12 background signal wells, respectively. Subse-
quent curve ﬁtting to determine the IC50 was with XLFit version
4.2 (IDBS) using a four-parameter dose response curve.
2.4. Veriﬁcation of primary hits and potency determination
Initial hits were (a) re-assayed at 30 lM for veriﬁcation and (b)
potency determined to generate an approximate IC50. Compounds
were transferred into columns 1 and 13 of a 384-well polypropyl-
ene plate (Matrix) and serially diluted in 100% DMSO through 10
half-log increments in row orientation using a JANUS 8-channel
Varispan automated workstation (PerkinElmer). This produced a
source plate containing thirty test and two standard inhibitor
curves (100 ﬁnal assay concentration) in columns 1–10 and 13–
22. An additional QC plate containing acetazolamide was also
generated. From these source plates 0.5 ll, corresponding to a ﬁnal
concentration range of 30 lM to 1.5 nM, were transferred into rep-
licate black 384-well polystyrene assay plates in duplicate. AfChiA1
and substrate were added as in the original screen.
Conﬁrmed hits were re-purchased from commercial sources
(Table 1 shows the corresponding structure of each compound
denoted in bold). Compounds 1, 2, 6 and 7 (ChemBridge Corpora-
tion, San Diego, CA, USA); compounds 3, 4 and 8 (ChemDiv, San
Diego, CA, USA); compounds 9 and 11 (Asinex Europe, Rijswijk,
NED); compound 5 (Maybridge, Fisher Scientiﬁc, Loughborough,
UK); compound 10 (InterBioScreen, Moscow, RUS) and compound
12 (Enamine, Monmouth, NJ, USA). For accurate duplicate potency
Table 1
Chemical structure of HTS compound hits identiﬁed against AfChiA1 and corresponding inhibitory constants across other GH18 family 18 chitinases. Compounds were assigned to
chemical series based on structural similarity.
Compound (series) Structure GH18 family chitinase IC50 (lM)
Plant-type Bacterial-type
AfChiA1a ScCTS1 AfChiB1 AMCase HsCHT
1 (1)
OO
O N
N
H
N
6
5 4
3
21
2.6 0.5 >100 9.8 >100
2 (2) O
N
N
N
Cl
34.9 N/D N/D N/D N/D
3 (3)
N
NH
O
S
HN
O
F
F
Br 6.6 N/D N/D N/D N/D
4 (3)
N
O
H2N
N
NH
19.4 >100 N/A N/A N/A
5 (4)
OH
ON
H
9.2 2.4 >100 >100 >100
6 (3)
N
N
OO
11.4 63.0 >100 >100 >100
7 (1)
N
HN
O
N
O
S
NH2
14.3 >100 N/A N/A N/A
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Table 1 (continued)
Compound (series) Structure GH18 family chitinase IC50 (lM)
Plant-type Bacterial-type
AfChiA1a ScCTS1 AfChiB1 AMCase HsCHT
8 (1)
N
O
S
NH2
O
HN
N
N
S
16.2 >100 N/A N/A N/A
9 (1)
N
N
N
H
N
O 11.8 >100 N/A N/A N/A
10 (1)
O
N
N
N
N
H
O
H2N O
45.3 >100 N/A N/A N/A
11 (2)
N
N H
N
O
Cl
58.8 >100 N/A N/A N/A
12 (1)
S N
NH
O
23.7 16.1 65.5 13.6 >100
N/D, not determined. N/A, not applicable.
a The IC50 values quoted for AfChiA1 are representative of the repeat potency determinations (performed in duplicate) and with the exception of compound 2 were within
5-fold of the original IC50.
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30 lM to 120 lM and diluted as described.
2.5. Inhibition proﬁles across the GH18 family chitinases
Counter screening assays to determine an IC50 against other
GH18 family chitinases included S. cerevisiae CTS1 (ScCTS1, model
plant-type chitinase) and three bacterial-type chitinases (A. fumig-
atus chitinase B1 [AfChiB], acidic mammalian chitinase [AMCase]
and Homo sapiens chitinase 1/chitotriosidase [HsCHT]). Assays
were performed as per AfChiA1 with the following modiﬁcations
[25,29]. Bacterial-type chitinases (AfChiB, AMCase and HsCHT) uti-
lised 4-methylumbelliferyl b-D-N-N-diacetylchitobioside (4MU-
NAG2) as a substrate [29] and for these pentoxifylline (Sigma)
was used as a control inhibitor [30]. Substrate concentrations for
IC50 determinations were selected according to the published Km
values for each enzyme [25,29,31,32]. The mode of inhibition
was established by Lineweaver–Burk plots of steady-state kinetics
with 50 lM to 1 mM of 4MU-GlcNAc3 in the presence of different
concentrations of selected compounds [23].2.6. Crystallography of AfChiA1 and ScCTS1 in complex with selected
HTS hits
Native crystals were obtained using the hanging (AfChiA1) and
sitting drop (ScCTS1) vapour diffusion methods using standard
protocols [23,25]. Crystals were soaked by the addition of 4 mM
of the respective ligand (AfChiA:compound 1 and ScCTS1:com-
pound 5; prepared from a 0.2 M stock in 100% DMSO) to a crystal-
lization drop. After incubation at 20 C for 30 min, crystals were
transferred to cryoprotectant (2.5 M Li2SO4 for AfChiA1 and 0.1 M
HEPES, 40% PEG 600 pH 7.5 for ScCTS1) using a nylon loop for
approximately 10 s before being ﬂash frozen in liquid nitrogen. Dif-
fraction data were collected at the European Synchrotron Radiation
Facility (ESRF) in Grenoble, France. Diffraction data were processed
and scaled with the HKL suite [33] to resolutions of 1.9 Å
(AfChiA:compound 1) and 1.8 Å (ScCTS1:compound 5), respec-
tively. Each complex was solved by manual molecular replacement
with the apo structure of AfChiA1 (PBD ID 2XVP [23]) or ScCTS1
(PDB ID 2UY2, [25]). Programs from the CCP4 suite [34] were used
throughout the reﬁnement process, which was initiated by
3286 D.E.A. Lockhart et al. / FEBS Letters 588 (2014) 3282–3290rigid-body reﬁnement and proceeded through iterative cycles of
minimisation using REFMAC5 [35] and model building with Coot
[36]. Ligand coordinates and topologies were produced with PROD-
RG [37]; ligands were not included until their conformations were
completely deﬁned by unbiased rA-weighted |Fo|  |Fc|, ucalc elec-
tron density maps. Further reﬁnement yielded the ﬁnal models
described in Table S2. Figures were generated using PyMol [38].
3. Results and discussion
3.1. High-throughput screening identiﬁes novel AfChiA1 inhibitors
Further exploration of chitinases as potential antifungal targets
requires new potent chemical tools for the plant-type subclass to
complement the nanomolar inhibitor, bisdionin C, discovered for
AfChiB [39]. To identify new AfChiA1 inhibitor scaffolds, a HTS
was performed using a ﬂuorescent assay. The Dundee Drug Discov-
ery Unit (DDU) diversity set containing 59,904 compounds was
screened against AfChiA1 at 30 lM. This purpose-designed library
adheres to lead-like properties of drug-like compounds [40]. The
172 assay screening plates generated a robust mean Z factor
(±SD) of 0.79 (±0.05) indicative of an excellent assay with wide
separation between the high and low controls [28]. The hit distri-
bution proﬁle (Fig. 1) showed nearly half of the library compounds
(28,094/59,904) clustered around an AfChiA1 inhibition of 1–10%.
Primary screening identiﬁed 48 compounds with P35% inhibition
(0.08% hit rate) using greater than two times the standard devia-
tion of the mean of the uninhibited control signal across all screen-
ing plates as a threshold. All 48 compounds were selected for re-
conﬁrmation and potency determination in duplicate
(R2 = 0.9991, Fig. 1) using 10-point dose–response curves. From
this, 23 compounds were veriﬁed hits with inhibition rates P35%
in two separate experiments giving an overall conﬁrmed hit rate
of 0.04%. Hits were ranked according to IC50 and 12 compounds
produced values 620 lM with the most potent hit (compound 1,
Table 1) returning an initial IC50 of 1.7 lM. Compounds were
grouped into four chemical series according to their structural sim-
ilarity (Table 1). Series 1 included the top hit and six additional
compounds with a common heterocyclic core: a six-membered
substructure fused to either a ﬁve- or six-membered ring. On the
other hand, compound (5) was the sole member of series 4. After
re-purchasing from the original vendor, hits were further evalu-
ated for AfChiA1 inhibition using a 10-point dilution series starting
at 120 lM. The results were in accordance (<5-fold difference)
with the original potency determinations with one exception
(compound 2, 15-fold increase).0 
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Fig. 1. HTS of AfChiA1 against the DDU diversity set. (A) Hit distribution proﬁle representi
that displayed a PI equal to or greater than two standard deviation units above the me
primary screen hits. A R2 value of 1.0 indicates the regression line perfectly ﬁts the data3.2. Two compounds selectively inhibit plant-type chitinases in the low
micromolar range
Of the conﬁrmed hits identiﬁed by HTS, we wished to identify
those selective for plant-type fungal chitinases in general. Given
apparent redundancy in this enzyme class we postulated that scaf-
folds possessing pan plant-type chitinase inhibition provide more
favourable tools for probing biological function than those with
selectivity towards an individual enzyme within the family. The
amino acid residues lining active site of the ﬁve plant-type chitin-
ases in A. fumigatus are completely conserved apart from a single
tyrosine residue (Y125) in AfChiA1 [26]. Based on this, AfChiA1 is
considered a suitable model for the active sites of AfChiA2–5. Addi-
tionally, we chose the well-characterised plant-type chitinase from
S. cerevisiae (ScCTS1), which has close homologs in Candida albicans
(CHT1–3) [41] as well as, putatively, in Aspergillus ﬂavus, Aspergillus
niger, Aspergillus clavatus and Aspergillus oryzae, as a second ‘refer-
ence’ plant-type chitinase. To investigate our hypothesis, ten hits
representative of each chemical series were evaluated for inhibi-
tion against two model plant-type chitinases. Of these, six com-
pounds (4, 7, 8, 9, 10 and 11) did not show signiﬁcant inhibition
of ScCTS1 with IC50 values exceeding 100 lM suggestive of discrep-
ancies towards substrate binding and/or speciﬁcity between the
two plant-type chitinases. Given our selection criteria these hits
were not further evaluated. Previous work [25] revealed the active
site pocket in A. fumigatus is shallower than in S. cerevisiae due to a
large methionine (Met310) side chain and this may account for
these hits having greater afﬁnity for AfChiA1 than ScCTS1. On the
other hand, four compounds (1, 5, 6 and 12) inhibited both AfChiA1
and ScCTS1 within half an order of magnitude suggestive of a com-
mon binding mode (Table 1) and pan plant-type chitinase activity.
Compounds 1 and 5 are of particular interest with IC50 values
<10 lM for both AfChiA1 and ScCTS1.
Next, we assessed the selectivity of compounds 1, 5, 6 and 12
across GH18 family chitinases. In particular we sought to identify
compounds only with selectivity towards plant-type chitinases to
complement existing nanomolar inhibitors of the bacterial-type
chitinases. Counter screening was performed against three bacte-
rial-type chitinases: A. fumigatus chitinase B1 [AfChiB], acidic
mammalian chitinase [AMCase] and H. sapiens chitinase 1/chitotri-
osidase [HsCHT]). The most potent hit, compound 1, had no activity
against AfChiB or HsCHT, but inhibited AMCase with a fourfold
drop-off in potency compared to AfChiA1 (Table 1). Compounds 5
and 6 were selective for plant-type chitinases with IC50 values
above 100 lM for all of the bacterial-type chitinases tested. Finally,
compound 12 displayed comparable activity between both classesPotency 1 vs Potency 2
R 2 = 0.9991
4.25
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Fig. 2. Lineweaver–Burk plots of compounds 1 (A) and 5 (B) measured against AfChiA1 using different concentrations of each inhibitor. The data were ﬁtted against a
competitive inhibition model and resulted in a Ki of 1.2 lM (compound 1) and 9.5 lM (compound 5). Km 300 ± 27 lM [23].
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chitin is absent from humans, the human genome includes two
active bacterial-type chitinases HsCHT and AMCase. Despite exten-
sive work the precise role of these enzymes is unresolved although
they may offer a protective role [12]. Hence, we wished to focus on
potent scaffolds that did not display selectivity towards these
enzymes.
Additional kinetic experiments were performed on compounds
1, 5 and 6 against AfChiA1. Steady state kinetics were measured to
determine the mode of inhibition and the corresponding inhibition
constant, Ki. Inhibitor concentrations were chosen according to thepreviously determined AfChiA1 IC50 (Table 1). Lineweaver–Burk
analysis indicates that each compound competes with the
pseudo-substrate 4MU-GlcNAc3 for binding to the AfChiA1 active
site (Fig. 2). Inhibition constants were 1.2 lM, 9.5 lM and
10.6 lM for compounds 1, 5 and 6 respectively.
3.3. Crystal structures of compound 1 and 5 reveal a competitive
binding mode
As compounds 1 and 5 were thought to represent the most
promising inhibitor scaffolds, we determined the molecular basis
3288 D.E.A. Lockhart et al. / FEBS Letters 588 (2014) 3282–3290of binding to allow for the future design of derivatives. AfChiA1
crystals were soaked with compound 1, diffraction data were col-
lected and scaled to 1.9 Å resolution, the AfChiA1-compound 1
complex structure solved by molecular replacement and reﬁned
to an Rfree of 0.22 (Table S2). Electron density corresponding to
the ligand (compound 1) was observed in the active site for both
molecules in the asymmetric unit. As previously observed [26],
the active site was partially obstructed in chain A by a symme-
try-related protein molecule and further discussion focuses on
chain B. Comparison of the AfChiA-compound 1 complex with a
published AfChiA-acetazolamide complex (PBD 2XTK [26])
revealed similar overall conformations with an RMSD of 0.15 Å
for 309 Ca atoms. Compound 1 consists of two ring systems, an
isoxazolopyrimidine stacking on Trp312 and an attached methoxy-
benzene. The pyrimidine moiety inserts deeply into the AfChiA
active site and thus is likely most important for binding (Fig. 3A).
The 6-methyl of the pyrimidine moiety inserts into a pocket at
the bottom of the binding cleft that is formed by Tyr34, Met310,
Ala205 and Gln230. Residues lining the AfChiA1 active site form
a number of hydrogen bonds with the ligand (Fig. 3A): the N1 ring
atom donates a hydrogen bond to the side chain of Asp172, while
the pyrimidine carbonyl group originating from the C2 position
accepts a hydrogen bond from the backbone amine of Ala124
and the N5 ring atom accepts a third hydrogen bond from the side
chain hydroxyl of Tyr232. The isoxazolo moiety points out of the
binding cleft (Fig. 3A). It forms no direct hydrogen bonds with
the protein, but engages in a (weak) water-mediated hydrogenA
B
A124
F60
E174
D172
A205Q230
Y232
N233
M310
Y34
W312A279
Q37
Fig. 3. Stereo view of HTS hit compounds (purple) binding to the active site of plant-typ
Surface representation of the protein active site is shown as a grey cartoon. Side chains
sticks and labelled. Potential hydrogen bonds are indicated by black dotted lines, a wat
AfChiA1 is represented as a red sphere. The unbiased (calculated before the addition of
(purple) is contoured at 3.0 r.bonding interaction with the side chain amide of Asn233 and the
backbone carbonyl of Ala279. The methoxyphenyl moiety makes
limited van der Waals contacts with the side chains of Trp312,
Gln37, Phe60 and Ala124, but otherwise points towards the bulk
solvent suggesting that the ring could be replaced. Crucially, com-
pound 1 only interacts with side chains that are identical in all ﬁve
AfChiA enzymes. Strikingly the non-conserved Tyr125 side chain
has ﬂipped out to accommodate the methoxy group of the isoxaz-
olo moiety and this may account for the improved inhibition of
compound 1 over acetazolamide in AfChiA1 by facilitating tight
interactions of the neighbouring pyrimidine moiety within the
depths of binding pocket. In ScCTS1 a serine residue replaces the
bulky ﬂexible tyrosine unique to AfChiA1 at the opening of the
active site pocket. Interestingly both acetazolamide [26] and com-
pound 1 displayed greater potency (8 and 5-fold respectively)
against ScCTS1 compared to AfChiA1 providing contributory evi-
dence that Tyr125 is not required for ligand speciﬁcity in plant-
type chitinases.
Exhaustive attempts to obtain a complex of compound 5 with
AfChiA1 were unsuccessful. Due to comparable IC50 values
between AfChiA1 and ScCTS1 (9.2 lM versus 2.4 lM, Table 1), as
an alternative approach, we selected ScCTS1 as a model to study
this interaction. The beta-barrel containing the active site is highly
conserved between ScCTS1 (PDB 2UY2 [25]) and AfChiA1 (PDB
2XVP [23]) with an RMSD of 1.2 Å for 270 Ca atoms providing fur-
ther rationale for our choice of surrogate. Compound 5 was soaked
into ScCTS1 crystals and diffraction data were collected to 1.8 Å.A124
F60
E174
D172
A205Q230
Y232
N233
M310
Y34
W312A279
Q37
e chitinases. (A) Compound 1 bound to AfChiA1. (B) Compound 5 bound to ScCTS1.
of key amino acid residues interacting with the ligand (purple) are depicted as grey
er molecule participating in indirect hydrogen bonding between compound 1 and
the ligand to the model) |Fo|  |Fc|, ucalc electron density map covering each ligand
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a ﬁnal Rfree of 0.23 (Table S2). Clear electron density for compound
5 was observed in the active site (Fig. 3B), corroborating the kinet-
ics data showing that it, like compound 1, is a competitive inhibi-
tor. The ScCTS1–compound 5 complex (Fig. 3B) shows the ligand
ﬁlling a similar space to that occupied by compound 1 despite
the lack of obvious chemical similarities. The dihydroindene moi-
ety inserts into the same pocket as the pyrimidine methyl of com-
pound 1. The hydrogen bonding requirements of the Asp172 side
chain (Asp155 in ScCTS1) is satisﬁed by the linker amine of com-
pound 5, which also donates a potential hydrogen bond to the car-
boxylate of Glu157 (Glu174 in AfChiA1). Continuing the ‘hydrogen
bond zipper’, the linker hydroxyl of compound 5 also donates a
hydrogen bond to the Glu157 side chain. Finally the ether oxygen
of the ligand accepts a hydrogen bond from the Ala110 backbone
(equivalent to Ala124 in AfChiA1). An aromatic group stacking with
the active site tryptophan side chain (Trp312 in AfChiA1, Trp285 in
ScCTS1) is a feature common to both compound 1 and acetazola-
mide as well as numerous other family 18 chitinase inhibitors
[26]. Consequently, the absence of stacking moieties in compound
5 is unusual, though it may help explain the speciﬁcity of this mol-
ecule for plant-type over bacterial-type family 18 chitinases, as the
latter group generally possesses a second tryptophan that forms a
‘lid’ for the active site [39]. Bacterial-type chitinase inhibitors gen-
erally bind sandwiched between the two Trp side chains, suggest-
ing that these enzymes may have a stronger preference for ﬂat/
aromatic ligands. Binding of the bulky dihydroindene deep in the
ScCTS1 active site induces a conformational change in the protein,
with the side chain of Tyr214 (Tyr232 in AfChiA1) and the follow-
ing loop being pushed out by 2 Å compared to the superimposed
ScCTS1–acetazolamide complex structure. It is likely that binding
of compound 5 to AfChiA1 in an equivalent pose will require more
dramatic conformational changes to the binding site, as the dihy-
droindene-binding pocket is smaller in AfChiA1 due to the pres-
ence of Met310 (equivalent to Ala283 in ScCTS1) It is possible
that this explains the slight decrease in afﬁnity of compound 5
for AfChiA1 compared to ScCTS1.
4. Concluding remarks
Chitinases represent a fascinating group of enzymes from a
chemical perspective although their precise physiological roles
remain elusive. In particular, the bacterial-type family have been
extensively studied in terms of competitive inhibitors that
mimic the carbohydrate substrate interaction [39,42,43].
Although both a natural product cyclopentapeptide inhibitor
(argiﬁn [43]) and a synthesised derivative based on linking a
two-xanthine ring system (bisdionin C [39]) have high nanomo-
lar afﬁnities for AfChiB they provide limited starting-points for
plant-type chitinase inhibitors [23]. This is highlighted by fun-
damental differences in substrate speciﬁcity and active site
architecture between the different families. Comparison of the
crystal structures (AfChiA1 PDB 2XVP [23] and AfChiB1 PDB
1W9P [29]) of both chitinase subclasses in A. fumigatus reveals
a deep pocket unique to plant-type chitinases in the base of
the substrate binding groove. On the other hand, bacterial-type
chitinases posses a more shallow and accessible groove with
the tight binding of bisdionin C (AfChiB IC50 200 nM) attributed
to tryptophan stacking beyond the single one conserved
between AfChiA1 and AfChiB1 [39].
In contrast plant-type chitinases are underexplored in terms of
chemical inhibitors. Prior to this study the only reported plant-type
chitinase inhibitors were allosamidin [21], acetazolamide [26] and
guanylurea derivatives [23], all of which are remarkably poor in
terms of their inhibition against AfChiA1. Structurally they areunfavorable: allosamidin extends beyond the conserved binding
pocket while all attempts to obtain acetazolamide/guanylurea
based derivatives failed to improve potency.
Our HTS against AfChiA1 has provided novel, low micromolar
plant-type chitinase competitive inhibitors (Table 1) that allow
for tailored ligand speciﬁcity. Of the two hits for which we
obtained structural information to illustrate the binding mode
(Fig. 3), compound 1 (IC50 2.6 lM), a novel pyrimidinone scaffold,
could be a platform for chemical modiﬁcation to inhibit a broad
range of fungal plant-type chitinases and increase potency towards
nanomolar inhibition. Speciﬁcally, as the 6-methyl moiety of the
pyrimidine ring engages the depth of the AfChiA1 binding pocket
there may be scope for larger substituents in this position to fully
occupy this space. This is supported by the known binding mode of
acetazolamide, which interacts in the same pocket with an ethyl
group. Taken together with information derived from the ScCTS1-
compound 5 complex, an ideal substitution could involve anything
from a small methyl group to a more bulky ring in terms of size.
Due to the tight afﬁnity of the pyrimidine ring for the AfChiA bind-
ing pocket and three key hydrogen bond interactions (Fig. 3A) no
further extensions are possible. Currently the methoxyphenyl moi-
ety provides little contribution to binding and therefore could be
replaced. We hope these modiﬁcations will concurrently drive
selectivity further towards the plant-type chitinases and create
chemical tools to probe their biological role.
This work represents a signiﬁcant advance in generating chem-
ical starting points and provides a platform for the development of
nanomolar AfChiA1 inhibitors that are required to fully dissect the
biological importance of these fungal plant-type chitinases. Evi-
dence of an upregulation in plant-type chitinase activity in mature
A. fumigatus bioﬁlms is emerging suggestive of a role in the compo-
sition of the extracellular matrix potentially through the liberation
of extracellular DNA [18]. Intriguingly acetazolamide, a weak
plant-type chitinase inhibitor (AfChiA1 IC50 > 150 lM) [25,26],
was shown to reduce A. fumigatus bioﬁlm biomass [18]. If further
work elaborating our novel pyrimidinone scaffold succeeds and
the role of plant-type chitinases in A. fumigatus bioﬁlm maturation
is conclusive, this would open up translational prospects perhaps
one day leading to the clinical use of chitinase-inhibitors as anti-
bioﬁlm agents.
Acknowledgements
We wish to thank the Dundee Drug Discovery Unit for access to
the diversity set library and the European Synchrotron Radiation
Facility, Grenoble, for time at the beamline. This work was sup-
ported by a MRC Programme Grant (G0900138) and a Wellcome
Trust Senior Research Fellowship (WT087590MA) to D.M.F.v.A.
D.E.A.L. is the recipient of a MRC Clinical Research Training
Fellowship (G1100430). The structures have been deposited in
the Protein Data Bank with accession codes 4TX6 and 4TXE.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.febslet.
2014.07.015.
References
[1] Brown, G.D., Denning, D.W., Gow, N.A., Levitz, S.M., Netea, M.G. andWhite, T.C.
(2012) Hidden killers: human fungal infections. Sci. Transl. Med. 4. 165rv113.
[2] Lass-Florl, C. (2009) The changing face of epidemiology of invasive fungal
disease in Europe. Mycoses 52, 197–205.
[3] Lin, S.J., Schranz, J. and Teutsch, S.M. (2001) Aspergillosis case-fatality rate:
systematic review of the literature. Clin. Infect. Dis. 32, 358–366.
3290 D.E.A. Lockhart et al. / FEBS Letters 588 (2014) 3282–3290[4] Agarwal, R., Chakrabarti, A., Shah, A., et al. (2013) Allergic bronchopulmonary
aspergillosis: review of literature and proposal of new diagnostic and
classiﬁcation criteria. Clin. Exp. Allergy 43, 850–873.
[5] Al-Shair, K., Atherton, G.T., Harris, C., Ratcliffe, L., Newton, P.J. and Denning,
D.W. (2013) Long-term antifungal treatment improves health status in
patients with chronic pulmonary aspergillosis: a longitudinal analysis. Clin.
Infect. Dis. 57, 828–835.
[6] Committee, J.F. (2013) British National Formulary (online), BMJ Group and
Pharmaceutical Press.
[7] Andes, D. (2013) Optimizing antifungal choice and administration. Curr. Med.
Res. Opin. 29 (Suppl. 4), 13–18.
[8] Epaulard, O., Villier, C., Ravaud, P., et al. (2013) A multistep voriconazole-
related phototoxic pathway may lead to skin carcinoma: results from a French
nationwide study. Clin. Infect. Dis. 57, e182–e188.
[9] Vermeulen, E., Lagrou, K. and Verweij, P.E. (2013) Azole resistance in
Aspergillus fumigatus: a growing public health concern. Curr. Opin. Infect.
Dis. 26, 493–500.
[10] Steinbach, W.J. (2013) Are we there yet? Recent progress in the molecular
diagnosis and novel antifungal targeting of Aspergillus fumigatus and invasive
aspergillosis. PLoS Pathog. 9, e1003642.
[11] Gastebois, A., Clavaud, C., Aimanianda, V. and Latge, J.P. (2009) Aspergillus
fumigatus: cell wall polysaccharides, their biosynthesis and organization.
Future Microbiol. 4, 583–595.
[12] Adrangi, S. and Faramarzi, M.A. (2013) From bacteria to human: a journey into
the world of chitinases, Biotechnol. Adv..
[13] Ruiz-Herrera, J. and San-Blas, G. (2003) Chitin synthesis as target for
antifungal drugs. Curr. Drug Targets Infect. Disord. 3, 77–91.
[14] Henrissat, B. (1991) A classiﬁcation of glycosyl hydrolases based on amino
acid sequence similarities. Biochem. J. 280 (Pt 2), 309–316.
[15] Seidl, V. (2008) Chitinases of ﬁlamentous fungi: a large group of diverse
proteins with multiple physiological functions. Fungal Biol. Rev. 22, 36–42.
[16] Alcazar-Fuoli, L., Clavaud, C., Lamarre, C., et al. (2011) Functional analysis of
the fungal/plant class chitinase family in Aspergillus fumigatus. Fungal Genet.
Biol. 48, 418–429.
[17] Jaques, A.K., Fukamizo, T., Hall, D., et al. (2003) Disruption of the gene
encoding the ChiB1 chitinase of Aspergillus fumigatus and characterization of a
recombinant gene product. Microbiology 149, 2931–2939.
[18] Rajendran, R., Williams, C., Lappin, D.F., Millington, O., Martins, M. and
Ramage, G. (2013) Extracellular DNA release acts as an antifungal resistance
mechanism in mature Aspergillus fumigatus bioﬁlms. Eukaryot. Cell 12, 420–
429.
[19] Loussert, C., Schmitt, C., Prevost, M.C., et al. (2010) In vivo bioﬁlm composition
of Aspergillus fumigatus. Cell. Microbiol. 12, 405–410.
[20] Beauvais, A., Schmidt, C., Guadagnini, S., et al. (2007) An extracellular matrix
glues together the aerial-grown hyphae of Aspergillus fumigatus. Cell.
Microbiol. 9, 1588–1600.
[21] Sakuda, S., Isogai, A., Matsumoto, S. and Suzuki, A. (1987) Search for microbial
insect growth regulators. II. Allosamidin, a novel insect chitinase inhibitor. J.
Antibiot. (Tokyo) 40, 296–300.
[22] Schuttelkopf, A.W., Andersen, O.A., Rao, F.V., et al. (2006) Screening-based
discovery and structural dissection of a novel family 18 chitinase inhibitor. J.
Biol. Chem. 281, 27278–27285.
[23] Rush, C.L., Schuttelkopf, A.W., Hurtado-Guerrero, R., et al. (2010) Natural
product-guided discovery of a fungal chitinase inhibitor. Chem. Biol. 17, 1275–
1281.
[24] Sutherland, T.E., Andersen, O.A., Betou, M., et al. (2011) Analyzing airway
inﬂammation with chemical biology: dissection of acidic mammalian
chitinase function with a selective drug-like inhibitor. Chem. Biol. 18, 569–
579.[25] Hurtado-Guerrero, R. and van Aalten, D.M. (2007) Structure of Saccharomyces
cerevisiae chitinase 1 and screening-based discovery of potent inhibitors.
Chem. Biol. 14, 589–599.
[26] Schuttelkopf, A.W., Gros, L., Blair, D.E., Frearson, J.A., van Aalten, D.M. and
Gilbert, I.H. (2010) Acetazolamide-based fungal chitinase inhibitors. Bioorg.
Med. Chem. 18, 8334–8340.
[27] Inglese, J., Shamu, C.E. and Guy, R.K. (2007) Reporting data from high-
throughput screening of small-molecule libraries. Nat. Chem. Biol. 3, 438–441.
[28] Zhang, J.H., Chung, T.D. and Oldenburg, K.R. (1999) A simple statistical
parameter for use in evaluation and validation of high throughput screening
assays. J. Biomol. Screen. 4, 67–73.
[29] Rao, F.V., Houston, D.R., Boot, R.G., et al. (2005) Speciﬁcity and afﬁnity of
natural product cyclopentapeptide inhibitors against A. fumigatus, human, and
bacterial chitinases. Chem. Biol. 12, 65–76.
[30] Rao, F.V., Andersen, O.A., Vora, K.A., Demartino, J.A. and van Aalten, D.M.
(2005) Methylxanthine drugs are chitinase inhibitors: investigation of
inhibition and binding modes. Chem. Biol. 12, 973–980.
[31] Renkema, G.H., Boot, R.G., Muijsers, A.O., Donker-Koopman, W.E. and Aerts,
J.M. (1995) Puriﬁcation and characterization of human chitotriosidase, a novel
member of the chitinase family of proteins. J. Biol. Chem. 270, 2198–2202.
[32] Chou, Y.T., Yao, S., Czerwinski, R., et al. (2006) Kinetic characterization of
recombinant human acidic mammalian chitinase. Biochemistry 45, 4444–
4454.
[33] Otwinowski, Z. and Minor, W. (2001) Denzo & Scalepack, Kluwer Academic
Publishers, London.
[34] Winn, M.D., Ballard, C.C., Cowtan, K.D., et al. (2011) Overview of the CCP4 suite
and current developments. Acta Crystallogr. D 67, 235–242.
[35] Vagin, A.A., Steiner, R.A., Lebedev, A.A., et al. (2004) REFMAC5 dictionary:
organization of prior chemical knowledge and guidelines for its use. Acta
Crystallogr. D 60, 2184–2195.
[36] Emsley, P., Lohkamp, B., Scott, W.G. and Cowtan, K. (2010) Features and
development of coot. Acta Crystallogr. D 66, 486–501.
[37] Schuttelkopf, A.W. and van Aalten, D.M. (2004) PRODRG: a tool for high-
throughput crystallography of protein–ligand complexes. Acta Crystallogr. D
60, 1355–1363.
[38] L. Schrodinger, The PyMOL Molecular Graphics System. Version 1.5.0.4.
[39] Schuettelkopf, A.W.A.O., Rao, F.V., Allwood, M., Rush, C.L., Eggleston, I.M. and
van Aalten, D.M. (2011) Bisdionin C – a rationally designed, submicromolar
inhibitor of family 18 chitinases. ACS Med. Chem. Lett. 2, 428–432.
[40] Brenk, R., Schipani, A., James, D., et al. (2008) Lessons learnt from assembling
screening libraries for drug discovery for neglected diseases. ChemMedChem
3, 435–444.
[41] McCreath, K.J., Specht, C.A., Liu, Y. and Robbins, P.W. (1996) Molecular cloning
of a third chitinase gene (CHT1) from Candida albicans. Yeast 12, 501–504.
[42] Rao, F.V., Houston, D.R., Boot, R.G., Aerts, J.M., Sakuda, S. and van Aalten, D.M.
(2003) Crystal structures of allosamidin derivatives in complex with human
macrophage chitinase. J. Biol. Chem. 278, 20110–20116.
[43] Houston, D.R., Shiomi, K., Arai, N., et al. (2002) High-resolution structures of a
chitinase complexed with natural product cyclopentapeptide inhibitors:
mimicry of carbohydrate substrate. Proc. Natl. Acad. Sci. USA 99, 9127–9132.
Further reading
[44] Brand, S., Cleghorn, L.A., McElroy, S.P., et al. (2012) Discovery of a novel class
of orally active trypanocidal N-myristoyltransferase inhibitors. J. Med. Chem.
55, 140–152.
